No Data
No Data
SSY Group Increases Sales Forecast for 2024
SSY Gets Registration Go-Ahead for Vasodilation-Induced Low BP Drug in China
SSY Group Announces Drug Registration Milestone
SSY Group (02005.HK): The hydrochloride of norepinephrine has been approved and registered by the Drug Administration Bureau as an active pharmaceutical ingredient for use in marketed preparations.
SSY Group (02005.HK) announced on July 23rd that its hydrochloride norepinephrine had been approved and registered by the Chinese National Medical Products Administration as an active pharmaceutical ingredient for use in listed preparations. Hydrochloride norepinephrine is mainly used to treat hypotension caused by vasodilation during anesthesia.
Express News | SSY Group - Phenylephrine Hydrochloride Has Obtained Approval for Registration From Nmpa of China
SSY Group's New Drugs Gain Market Approval
No Data